NICE Changes Stance on Genmab's Cervical Cancer Drug

Why It Matters

The endorsement gives UK patients a clinically superior option while meeting NHS cost‑effectiveness standards, and it unlocks a major growth engine for Genomab’s independent oncology portfolio.

Key Takeaways

• NICE now endorses Tivdak for recurrent/metastatic cervical cancer.
• Median overall survival improves to 11.5 months versus 9.5 months.
• Revised economic model satisfied NHS cost‑effectiveness criteria.
• Cancer Drugs Fund will fund initial Tivdak access in the UK.
• Genomab forecasts up to $600 million peak global sales.

Pulse Analysis

Cervical cancer remains a pressing public‑health challenge in the United Kingdom, with roughly 3,300 new diagnoses and 900 deaths each year. While early‑stage disease benefits from vaccination and screening, women with recurrent or metastatic disease face limited therapeutic choices, typically confined to chemotherapy. Health technology assessments such as those conducted by NICE play a pivotal role in determining whether innovative, often expensive, treatments can be adopted within the NHS framework, balancing clinical benefit against budgetary constraints.

Tivdak (tisotumab vedotin) entered the UK market after the MHRA approved it as a chemotherapy alternative in December. The pivotal innovaTV 301 trial demonstrated a median overall survival of 11.5 months, a two‑month gain over standard chemotherapy and a 30% reduction in death risk. By integrating five‑year real‑world data and updated cost inputs for comparator therapies, Genomab’s revised economic model satisfied NICE’s cost‑effectiveness threshold, prompting the agency to issue draft guidance recommending Tivdak. The Cancer Drugs Fund will bridge the gap, providing patients with immediate access while the NHS finalizes routine commissioning.

For Genomab, the NICE decision marks a watershed moment. The drug is the company’s first solo launch, and early U.S. sales handled by Pfizer have already generated $39 million in Q1 revenue. Analysts anticipate a trajectory toward $600 million in peak global sales as European roll‑out accelerates. The endorsement not only validates the commercial viability of antibody‑drug conjugates but also signals to investors that Genomab can navigate complex reimbursement landscapes without relying on partner networks, strengthening its position in the competitive oncology market.